Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect [Yahoo! Finance]
Immuron Limited - American Depositary Shares (IMRN)
US:NASDAQ Investor Relations:
immuron.com/investor-centre/business-overview
Company Research
Source: Yahoo! Finance
Thursday 8 th August 2024, 11:00am Australian Eastern Standard Time (9:00am AWST). Chief Executive Officer, Steven Lydeamore will provide an update on additional data analysis of IMM-124E (Travelan ® ) Phase 2 trial and next steps. Following the presentation, attendees will have the opportunity to ask questions directly to Mr. Lydeamore during a moderated Q & A session. This webinar can be viewed live via zoom & you register for FREE via the link below. https://us06web.zoom.us/webinar/register/WN_QV-yMVvGRQuYq698XMTQxA A recorded copy of the webinar will be made available following the event. This release has been authorised by the directors of Immuron Limited. COMPANY CONTACT: Steven Lydeamore Chief Executive Officer steve@immuron.com About Immuron Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious disease
Show less
Read more
Impact Snapshot
Event Time:
IMRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMRN alerts
High impacting Immuron Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
IMRN
News
- Traveler's Diarrhea Therapeutics Pipeline Market Report 2024 Featuring Immuron, Scandinavian Biopharma, and Sigmoid Pharma [Yahoo! Finance]Yahoo! Finance
- Immuron Plans Phase 2 Trial for IMM-529 following FDA reviewGlobeNewswire
- US DoD grants $2.3m to Immuron for military version of anti-diarrhoeal Travelan [Yahoo! Finance]Yahoo! Finance
- Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan®GlobeNewswire
- Immuron CEO, Steven Lydeamore to present at the Emerging Growth ConferenceGlobeNewswire
IMRN
Sec Filings
- 9/26/24 - Form 6-K
- 9/9/24 - Form 6-K
- 9/5/24 - Form 6-K
- IMRN's page on the SEC website